Paul Bisaro

Paul M. Bisaro brings deep operational and strategic insight to the Board, with more than 30 years of business, management, and leadership experience in the pharmaceutical industry. He served as our Chairman of the Board of Directors from February 2024 to July 2025 and from June 2022 to November 2023. 

Mr. Bisaro currently serves on the boards of Pleo Pharma, Zoetis Inc., and Myriad Genetics, Inc., having joined in April 2020, May 2015, and October 2022, respectively. Past board service includes TherapeuticsMD from 2020 to 2022 and Zimmer Biomet Holdings, Inc. from 2013 to 2017. His executive experience spans roles such as Executive Chairman at Amneal Pharmaceuticals, Inc. from 2018 to 2019 and Allergan from 2014 to 2016, as well as CEO positions at Actavis plc (formerly Watson Pharmaceuticals) and Impax Laboratories. 

Mr. Bisaro earned an undergraduate degree from the University of Michigan and a Juris Doctor from the Catholic University of America.